anticorpos de interleucina-20 anti-humanos, assim como método de produção dos mesmos

Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivati...

Full description

Saved in:
Bibliographic Details
Main Authors JES THORN CLAUSEN, JESPER PASS, SOREN OSTERGAARD
Format Patent
LanguagePortuguese
Published 20.10.2015
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Anti-human IL20 monoclonal antibodies that can reduce IL20 mediated activation of both IL20R1/IL20R2 and IL22R1/IL20R2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders.
Bibliography:Application Number: BR2009PI14916